Leroux B, Rose J P, Potron G, Grun G, Droulle C, Mesmin F, Gomes H
Nouv Presse Med. 1976 Mar 13;5(11):699-702.
The authors present the results obtained using a therapeutic combinaison of plasminogen-urokinase in vivo in 14 premature infants suffering from respiratory distress. 86 % survived, a considerable improvement over classical survival rates. In addition it appeared that the duration of oxygen therapy was shorter, secondary to limitation of extension of the disease.
作者展示了在14名患有呼吸窘迫的早产儿体内使用纤溶酶原 - 尿激酶治疗组合所获得的结果。86%的患儿存活，这比传统存活率有了显著提高。此外，由于疾病扩展受限，吸氧治疗的持续时间似乎缩短了。
